Research Topics
| G A AbelSummaryAffiliation: Harvard University Country: USA Publications
|
Detail Information
Publications
Delays in referral and diagnosis for chronic hematologic malignancies: a literature reviewGregory A Abel
Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
Leuk Lymphoma 49:1352-9. 2008..Unfortunately, the outcomes associated with such delays are largely unreported, possibly because delay is complex to define and difficult to measure...- Chemotherapy as language: sound symbolism in cancer medication namesGregory A Abel
Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Smith 271, Boston, MA 02115, USA
Soc Sci Med 66:1863-9. 2008..This finding raises important questions about the possible role of the names of medications in the experiences of cancer patients and providers... - Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claimsG A Abel
Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Thromb Haemost 6:1680-4. 2008..DTCA for medications to treat rare diseases such as bleeding disorders is unlikely to be given high priority for FDA review... - Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatmentGregory A Abel
Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA
J Clin Oncol 27:4182-7. 2009..Although cancer-related direct-to-consumer advertising (CR-DTCA) is prevalent, little is known about cancer patients' experiences with this controversial medium of medical communication... - Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) ProgramGregory A Abel
Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Hematol Oncol 28:133-6. 2010..26 [1.07, 1.48]). Our analysis suggests that, at least among white women, SEER is a reliable data source with respect to lymphoid malignancies... - Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patientsGregory A Abel
Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Leuk Res 34:939-41. 2010..It is not known to what extent the WHO classification scheme for MDS has been adopted in clinical practice... - Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 26:5107-12. 2008..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers... - Direct-to-consumer advertising in oncologyGregory A Abel
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114-2617, USA
Oncologist 11:217-26. 2006..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed... - Direct-to-consumer advertising in oncology: a content analysis of print mediaGregory A Abel
Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 25:1267-71. 2007..Content analysis of cancer-related direct-to-consumer advertising (DTCA), with a focus on how benefit and risk/adverse effect information is presented, is essential to understanding its potential impact on oncology outcomes...